Patent · US Expired

Fused bicyclic inhibitors of HCV

US8030318B2 · kind B2 · utility

28Cited by

2References

3Claims

0Family size

Assignee

Tibotec Pharmaceuticals Ltd. · IE

Inventors

Kenneth Alan Simmen · Tervuren, BE
Dominique Louis Nestor Ghislain Surleraux · Braine-le-Comte, BE
Tse-I Lin · Mechelen, BE
Oliver Lenz · Sint-Katelijne-Waver, BE
Pierre Jean-Marie Bernard Raboisson · Sligo, IE
Sarvajit Chakravarty · Sunnyvale, US
Barry Hart · Palo Alto, US

Key dates

Filing date	Mar 27, 2006
Grant date	Oct 4, 2011
Priority date	—
Expiry date	Mar 29, 2026

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Substituted fused bicyclic pyrimidine compounds having an amide-substituted pyridylamine group at C-4 of the pyrimidine ring are useful in the treatment of conditions associated with HCV.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.